XIAP and ovarian carcinoma: Additionally, the degradation of the X-linked inhibitor of apoptosis protein (XIAP) by HtrA1 plays a role in the cellular response to chemotherapy, suggesting that restoring HtrA1 expression could be a promising therapeutic approach for treating ovarian cancer [24].